Pancreatic ductal adenocarcinoma (PDA) is characterized by abundant infiltration of tumor-associated macrophages (TAMs). TAMs have been reported to drive resistance to gemcitabine, a frontline chemotherapy in PDA, though the mechanism of this resistance remains unclear. Profiling metabolite exchange, we demonstrate that macrophages programmed by PDA cells release a spectrum of pyrimidine species. These include deoxycytidine, which inhibits gemcitabine through molecular competition at the level of drug uptake and metabolism. Accordingly, genetic or pharmacological depletion of TAMs in murine models of PDA sensitizes these tumors to gemcitabine. Consistent with this, patients with low macrophage burden demonstrate superior response to gemcitabine treatment. Together, these findings provide insights into the role of macrophages in pancreatic cancer therapy and have potential to inform the design of future treatments. Additionally, we report that pyrimidine release is a general function of alternatively activated macrophage cells, suggesting an unknown physiological role of pyrimidine exchange by immune cells.
Keywords: deoxycytidine; gemcitabine resistance; immunometabolism; macrophage; metabolic crosstalk; metabolomics; pancreatic cancer; pancreatic ductal adenocarcinoma; tumor microenvironment; tumor-associated macrophage.
Copyright © 2019 Elsevier Inc. All rights reserved.
Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase.Oncogene. 2014 Jul 17;33(29):3812-9. doi: 10.1038/onc.2013.357. Epub 2013 Sep 2. Oncogene. 2014. PMID: 23995783
Gemcitabine resistance in pancreatic ductal adenocarcinoma.Drug Resist Updat. 2015 Nov;23:55-68. doi: 10.1016/j.drup.2015.10.002. Epub 2015 Nov 3. Drug Resist Updat. 2015. PMID: 26690340 Review.
Transfer of miRNA in Macrophage-Derived Exosomes Induces Drug Resistance in Pancreatic Adenocarcinoma.Cancer Res. 2018 Sep 15;78(18):5287-5299. doi: 10.1158/0008-5472.CAN-18-0124. Epub 2018 Jul 24. Cancer Res. 2018. PMID: 30042153
Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models.Dis Model Mech. 2016 Dec 1;9(12):1461-1471. doi: 10.1242/dmm.026369. Epub 2016 Oct 20. Dis Model Mech. 2016. PMID: 27780828 Free PMC article.
Impact of tumour associated macrophages in pancreatic cancer.BMB Rep. 2013 Mar;46(3):131-8. doi: 10.5483/bmbrep.2013.46.3.036. BMB Rep. 2013. PMID: 23527856 Free PMC article. Review.
Cited by 23 articles
Polymer nanoparticle-assisted chemotherapy of pancreatic cancer.Ther Adv Med Oncol. 2020 May 8;12:1758835920915978. doi: 10.1177/1758835920915978. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32426046 Free PMC article. Review.
Lack of CD8+ T-cell co-localization with Kaposi's sarcoma-associated herpesvirus infected cells in Kaposi's sarcoma tumors.Oncotarget. 2020 Apr 28;11(17):1556-1572. doi: 10.18632/oncotarget.27569. eCollection 2020 Apr 28. Oncotarget. 2020. PMID: 32391124 Free PMC article.
Metabolic reprogramming and cancer progression.Science. 2020 Apr 10;368(6487):eaaw5473. doi: 10.1126/science.aaw5473. Science. 2020. PMID: 32273439 Free PMC article. Review.
A non-proliferative role of pyrimidine metabolism in cancer.Mol Metab. 2020 May;35:100962. doi: 10.1016/j.molmet.2020.02.005. Epub 2020 Feb 13. Mol Metab. 2020. PMID: 32244187 Free PMC article. Review.
Gemcitabine Recruits M2-Type Tumor-Associated Macrophages into the Stroma of Pancreatic Cancer.Transl Oncol. 2020 Mar;13(3):100743. doi: 10.1016/j.tranon.2020.01.004. Epub 2020 Mar 4. Transl Oncol. 2020. PMID: 32145636 Free PMC article.
- UL1 TR000433/TR/NCATS NIH HHS/United States
- R01 CA198074/CA/NCI NIH HHS/United States
- P30 CA046592/CA/NCI NIH HHS/United States
- F32 CA228328/CA/NCI NIH HHS/United States
- T32 GM113900/GM/NIGMS NIH HHS/United States
- R01 CA151588/CA/NCI NIH HHS/United States
- K08 CA234222/CA/NCI NIH HHS/United States
- UL1 TR002240/TR/NCATS NIH HHS/United States
- U24 DK097153/DK/NIDDK NIH HHS/United States
- U01 CA224145/CA/NCI NIH HHS/United States
- CRUK_/Cancer Research UK/United Kingdom
- FLF2015_04_GLASGOW/PANCREATICCANUK_/Pancreatic Cancer UK/United Kingdom
- T32 CA009676/CA/NCI NIH HHS/United States
- P30 DK034933/DK/NIDDK NIH HHS/United States
- T32 DK094775/DK/NIDDK NIH HHS/United States
- T32 AI007413/AI/NIAID NIH HHS/United States
- R50 CA232985/CA/NCI NIH HHS/United States